T
TCRX
vs
S&P 500
S&P 500
Over the past 12 months, TCRX has underperformed S&P 500, delivering a return of -70% compared to the S&P 500's +14% growth.
Stocks Performance
TCRX vs S&P 500
Performance Gap
TCRX vs S&P 500
Performance By Year
TCRX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
TScan Therapeutics Inc
Glance View
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The firm's lead liquid tumor TCR-T therapy candidates include TSC-100 and TSC-101, which are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation (HCT). TSC-100 and TSC-101 targets histocompatibility antigens (HA)-1 and HA-2 antigens, respectively. TScan solid tumor product candidates include TSC-200, TSC-201, TSC-202 and TSC-203. Its TSC-200 series of product candidates are being developed to treat both HPV-positive and HPV-negative tumors. The firm's platform technologies include TargetScan, ReceptorScan and T-Integrate.